<DOC>
	<DOCNO>NCT02013089</DOCNO>
	<brief_summary>Hypothesis : Different patient different biomarkers , doctor know biomarkers patient ; may able prescribe regimen well suit patient 's specific need . This pilot study . Here , use whole exon sequence Integrated genomic network analysis identify biomarker gene . We aim learn drug chosen base biomarkers help control metastatic gastrointestinal cancer fail standard available regimen .</brief_summary>
	<brief_title>A Pilot Study Genomic Sequencing Guided Individualized Therapy Gastrointestinal Cancers , GITIC Study</brief_title>
	<detailed_description>Rational : Cancer sequencing ( CS ) promise become centerpiece personalized oncology inform treatment target tumor 's unique genetic constitution . This data critical making inform decision disease management , though may case patient . CS identifies variation difference DNA and/or RNA cell individual 's tumor comparison his/her normal cell . These somatic variation may , interpretation , identify key driver carcinogenesis . Such information may predict patient 's prognosis , response currently available treatment prompt development novel therapeutic . Though CS potential personalize optimize cancer care , may produce vast amount data unique change DNA/RNA may difficult interpret present time . Using Integrated genomic network analysis , could better understand underlying process pathway involve tumor onset progression . And could choose specific treatment regimen develop personalized cancer therapy</detailed_description>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Pathologic diagnosis Gastrointestinal cancer 2 . The subject diagnosis metastatic gastrointestinal cancer , fail standard treatment , regimen available . 3 . The subject measurable lesion gastrointestinal cancer . 4 . The subject 's The Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 5 . The subject adequate hematologic function define absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 , platelet count &gt; /= 100,000/mm3 , White Blood Count ( WBC ) &gt; /= 3,000/ mm3 , hemoglobin &gt; /= 9 g/dL . 6 . The subject adequate hepatic function define total bilirubin level &lt; /= 1.5 * upper limit normal ( ULN ) ( bilirubin &gt; /= 1.5 * ULN known Gilbert 's disease allow ) , alkaline phosphatase , aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &lt; /= 2.5 * upper limit normal &lt; /= 5.0 * ULN liver metastases present . 7 . Serum creatinine clearance &gt; 50ml/min , either CockcroftGault formula 24hour urine collection analysis 8 . The subject &gt; /=18 year age . 9 . The subject sign informed consent . 10 . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Childbearing potential defined woman menses within past 12 month , tubal ligation , hysterectomy bilateral oophorectomy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 1. pregnant breastfeeding . 2 . Subjects exclude concurrent severe and/or uncontrolled medical disease could compromise participation study 3. without enough tumor sample analysis . 4 . Refuse sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>genomic sequencing , Integrated genomic network analysis</keyword>
</DOC>